The mission of the Curative Therapies for HIV Scientific Working Group (SWG) is to encourage the development of a cure for HIV, by fostering new ideas and promoting new technology. During the previous funding cycle this continuing SWG was highly successful in its efforts to bring together local researchers and community members with the aim of advancing cure research. As the HIV pandemic continues to affect many millions of lives globally, there is still an urgent need for an HIV cure, so we will continue to support research into curative therapies through our SWG. The long-term objective of our SWG is to stimulate novel research, which can progress into a cure for HIV that can ultimately be transitioned into the clinic, and reduce the global burden of HIV that remains. To achieve our mission the SWG will continue to bring together UW/Fred Hutch CFAR affiliated researchers, unaffiliated external HIV researchers, and community members, through a series of scientific networking events, forums and an annual conference, each with a defined purpose. The goals of this SWG will be attained through two specific aims that are intended to: 1) Provide infrastructure that fosters the exchange of new actionable ideas, engages the community, and promotes the development of novel curative treatments for HIV, and 2) Develop new intra-/inter-CFAR projects and funding applications on curative therapies for HIV. Cooperation between researchers and community members from local, national and international settings who are invested in the common goal of HIV cure will be key to the success of our mission. We plan to leverage recent NIH investment in the Seattle-led consortium defeatHIV, one of six Martin Delaney Collaboratories focused on the cure of HIV. We will work with UW/Fred Hutch CFAR cores and external researchers to exploit expertise across many areas, in order to develop novel research questions and subsequent grant applications for the study of curative therapies for HIV. We will also work closely with local, national, and international community members to learn what an HIV cure would mean to them, and to gain new perspectives into how an HIV cure can be realized. Collaboration is essential to our mission, and by working with people of broad experience and from diverse backgrounds we hope to serve as an internationally-recognized center for the study of curative therapies for HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-32
Application #
9693165
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
32
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Hamilton, Deven T; Goodreau, Steven M; Jenness, Samuel M et al. (2018) Potential Impact of HIV Preexposure Prophylaxis Among Black and White Adolescent Sexual Minority Males. Am J Public Health 108:S284-S291
Bilal, Usama; McCaul, Mary E; Crane, Heidi M et al. (2018) Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. Alcohol Clin Exp Res 42:561-570
Morgan, Ethan; Skaathun, Britt; Duvoisin, Rebeccah et al. (2018) Are HIV Seroconversions Among Young Men Who Have Sex With Men Associated With Social Network Proximity to Recently or Long-Term HIV-Infected Individuals? J Acquir Immune Defic Syndr 77:128-134
Wagner, Anjuli D; Njuguna, Irene N; Neary, Jillian et al. (2018) Financial Incentives to Increase Uptake of Pediatric HIV Testing (FIT): study protocol for a randomised controlled trial in Kenya. BMJ Open 8:e024310
Beima-Sofie, Kristin; Wamalwa, Dalton; Maleche-Obimbo, Elizabeth et al. (2018) Toll-like receptor 9 polymorphism is associated with increased Epstein-Barr virus and Cytomegalovirus acquisition in HIV-exposed infants. AIDS 32:267-270
Balkus, Jennifer E; Brown, Elizabeth R; Palanee-Phillips, Thesla et al. (2018) Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr 77:e8-e10
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Morgan, Ethan; Skaathun, Britt; Schneider, John A (2018) Sexual, Social, and Genetic Network Overlap: A Socio-Molecular Approach Toward Public Health Intervention of HIV. Am J Public Health 108:1528-1534
Fredericksen, R J; Gibbons, L; Brown, S et al. (2018) Medication understanding among patients living with multiple chronic conditions: Implications for patient-reported measures of adherence. Res Social Adm Pharm 14:540-544
Liu, Amy Y; De Rosa, Stephen C; Guthrie, Brandon L et al. (2018) High background in ELISpot assays is associated with elevated levels of immune activation in HIV-1-seronegative individuals in Nairobi. Immun Inflamm Dis 6:392-401

Showing the most recent 10 out of 1275 publications